forgemax.FORGED. TESTED. PROVEN.
Parabolan 76.5mg/ml 10ml Vial by Kim Pharma
Optimal Dosage

Parabolan 76.5mg/ml 10ml Vial by Kim Pharma

Kim Pharma Parabolan 76.5mg/ml is a long-acting injectable 19-nor androgen formulated as Trenbolone Hexahydrobenzylcarbonate at 76.5 mg per millilitre in a 10 ml multi-dose vial — defined pharmacologically by its direct, unmetabolised engagement of the androgen receptor, with competitive ligand-displacement studies placing receptor affinity at roughly four to five times that of testosterone. Sustained circulating Trenbolone concentrations across multi-day intervals are governed by the hexahydrobenzylcarbonate ester's depot-controlled hydrolysis, supporting a low-frequency injection schedule without sacrificing receptor-level exposure. Batch-level quality is confirmed through HPLC potency assay and LAL endotoxin testing; each vial carries a serialised hologram and authentication code linked to its production record.

€68.00Free shipping on orders over €300
In stock
Ships within 48 h Lab-tested batch
  • Exceptionally high androgen receptor binding affinity drives potent anabolic signalling at lower administered doses
  • 19-nor structural modification prevents aromatase-mediated oestrogen conversion, limiting water-retention risk
  • Depot-controlled ester release sustains receptor-level exposure between scheduled injection days
  • 76.5 mg/ml concentration enables precise volume-based dose arithmetic for structured weekly androgen management
  • 10 ml multi-dose vial format reduces per-cycle restocking frequency without compromising dose accuracy
  • Serialised hologram and batch-linked authentication code allow real-time verification of vial authenticity
  • HPLC potency assay and LAL endotoxin testing at batch level confirm concentration and sterility prior to release

Key takeaways

  • Prioritise receptor binding data: Trenbolone's AR affinity is 4–5× testosterone's.
  • Recognise the DHT lineage — no aromatisation, direct AR engagement only.
  • Verify each vial's hologram and authentication code before drawing a dose.
  • Calculate weekly androgen load using the exact 76.5 mg/ml concentration figure.
  • Store opened vials upright at 15–25 °C; check for clarity before every draw.

Trenbolone Hexahydrobenzylcarbonate: A High-Affinity Androgen Receptor Agonist

Kim Pharma Parabolan 76.5mg/ml is defined as a 19-nor DHT-derived injectable steroid whose pharmacological identity is determined primarily by its interaction with the androgen receptor (AR) rather than by conversion to secondary hormones. Trenbolone does not aromatise to oestrogen and does not undergo 5-alpha-reductase conversion to a more potent metabolite at target tissues — meaning the molecule that binds the receptor is identical to the molecule that arrives at it. This direct, unmetabolised receptor engagement is what separates Trenbolone from testosterone-based androgens in mechanistic terms.

Androgen Receptor Binding Affinity: The Mechanistic Core

Trenbolone Hexahydrobenzylcarbonate binds the androgen receptor with a relative binding affinity approximately 4–5× higher than testosterone, as established by competitive ligand-displacement assays in androgen-sensitive cell models. That figure matters because AR-mediated transcriptional output — the process by which androgen signalling drives nitrogen retention, IGF-1 pathway upregulation, and myofibrillar protein synthesis — scales with both receptor occupancy and agonist intrinsic efficacy. Trenbolone achieves high occupancy at lower circulating concentrations compared to testosterone, which is the mechanistic rationale for the lower milligram doses used clinically and in structured protocols. The molecule's DHT lineage means it carries a 4,5-double bond in the A-ring alongside the 19-nor modification, a structural combination that confers AR selectivity and resistance to enzymatic inactivation at the receptor-complex level.

How the Hexahydrobenzylcarbonate Ester Shapes Receptor Exposure

The hexahydrobenzylcarbonate group functions purely as a pharmacokinetic modulator: it is cleaved by tissue esterases at the injection depot, releasing free Trenbolone into circulation over an extended window measured in days rather than hours. This depot-controlled release means that AR occupancy builds gradually following injection and is maintained at meaningful levels between doses — a profile that translates mechanistically into sustained transcriptional signalling at target tissues. Compared to Trenbolone Acetate, which requires daily injections to maintain equivalent receptor-level exposure, the hexahydrobenzylcarbonate formulation delivers comparable cumulative AR stimulation with a significantly less frequent injection schedule, as documented in pharmacokinetic modelling of ester-controlled androgen release.

Quality Infrastructure Supporting Dose-Accurate Receptor Stimulation

Receptor-level pharmacology is only as precise as the dose delivered; Kim Pharma addresses this through HPLC potency assay and LAL endotoxin testing conducted at the batch level. Every 10 ml vial of Parabolan 76.5mg/ml is assigned a unique serialised code linked to its batch documentation, and tamper-evident holograms on the vial and outer packaging allow end users to verify authenticity before use.

Usage

  1. Confirm vial identity by scanning or visually verifying the Kim Pharma hologram and authentication code against the brand's verification portal before drawing any dose.
  2. Calculate your intended weekly androgen dose using the precise 76.5 mg/ml concentration — divide target weekly milligrams by 76.5 to determine exact injection volume in millilitres.
  3. Allow the vial to reach room temperature (15–25 °C) before drawing; cold carrier oil increases viscosity and makes consistent volume measurement difficult.
  4. Draw using a 21–23 gauge needle for the oil's viscosity, then swap to a fresh 23–25 gauge needle for intramuscular injection to ensure injection-site comfort and sterility.
  5. Administer intramuscularly into a large muscle (gluteus, lateral quadriceps, or deltoid), aspirating briefly before injection; rotate sites across the week's two injection days to reduce localised tissue stress.
  6. Log each injection date, volume, and site in a cycle diary — this record is essential for calculating the correct interval before beginning post-cycle therapy, given the extended ester release window of the hexahydrobenzylcarbonate formulation.

Warnings

Contraindications: Not indicated for individuals with diagnosed prostate or breast carcinoma, severe hepatic impairment, or untreated polycythaemia. Women of childbearing potential should not use this compound due to virilisation risk and teratogenicity associated with high-affinity androgen receptor agonists. Concurrent use of other high-AR-affinity androgens without adjusted total androgen load calculation is contraindicated.

Side Effects: Androgenic effects including accelerated scalp hair thinning, sebum overproduction, and vocal deepening may occur due to the compound's high AR binding affinity. Progestogenic receptor activity may elevate prolactin; monitor with baseline and mid-cycle prolactin assay. Cardiovascular risk includes suppression of HDL cholesterol and elevation of haematocrit — both measurable via standard lipid panel and CBC respectively. Night sweats and elevated resting heart rate are reported at higher doses and are dose-dependent.

Monitoring: Baseline bloodwork — including haematocrit, ALT, AST, fasted lipid panel, and prolactin — should be established before cycle initiation. Repeat at 4-week intervals during the active cycle. Haematocrit above 52 % warrants dose reduction or temporary suspension. Any persistent elevation of liver transaminases beyond 3× the upper limit of normal requires immediate cycle discontinuation.

PCT: Because the hexahydrobenzylcarbonate ester sustains active Trenbolone release from the depot for an extended window post-injection, post-cycle therapy should not commence immediately after the final dose. Calculate PCT start based on the known ester clearance window; SERM-based protocols (e.g. Nolvadex or Clomid) are the standard approach for restoring hypothalamic-pituitary-gonadal axis function following suppressive androgen use.

Frequently asked questions

How does Trenbolone Hexahydrobenzylcarbonate interact with the androgen receptor at a molecular level?
Trenbolone Hexahydrobenzylcarbonate binds the androgen receptor directly after ester cleavage releases free Trenbolone at the depot site. The free molecule occupies the AR ligand-binding domain with an affinity estimated at 4–5× that of testosterone by competitive radioreceptor assay. This high-occupancy binding drives AR nuclear translocation and transcriptional activation of genes governing nitrogen retention and muscle protein synthesis without requiring metabolic conversion.
Why does Trenbolone have a higher androgen receptor affinity than testosterone despite similar base structures?
The 19-nor modification and the 4,5-double bond in Trenbolone's A-ring create a ligand geometry that fits the AR binding pocket more tightly than testosterone's native structure. Additionally, Trenbolone is not reduced by 5-alpha-reductase into a weaker metabolite at muscle tissue — unlike testosterone, which converts partly to compounds with lower AR affinity — so the full binding potency of the parent molecule is preserved at the point of receptor interaction.
What does DHT-derived classification mean for Trenbolone's receptor selectivity and side-effect profile?
DHT-derived steroids structurally resist aromatisation to oestrogen because the A-ring modification that aromatase requires for conversion is absent. For Trenbolone this means estrogenic side effects — water retention, gynecomastia — are not driven by the compound itself, though prolactin elevation via progestin receptor activity remains a monitored variable. The selectivity for AR over oestrogen receptor is a direct consequence of this structural lineage and is the mechanistic basis for Trenbolone's lean-tissue–focused activity profile.
How should Kim Pharma Parabolan 76.5mg/ml 10ml vials be stored after first use to maintain potency?
After the rubber stopper is first punctured, the vial should be stored upright at room temperature (15–25 °C), away from direct light and heat sources; refrigeration is not required for oil-based injectables and can increase viscosity. Use a fresh sterile needle for each draw to preserve stopper integrity. The 10 ml format provides multiple doses from one vial; discard if the solution becomes cloudy or shows visible particulate matter.
Can insulin syringes be used to draw and inject Kim Pharma Parabolan 76.5mg/ml, and what volume does a typical dose represent?
Insulin syringes (0.5 ml or 1 ml, 27–29 gauge) can be used for subcutaneous injection but are not recommended for intramuscular administration of oil-based solutions due to bore restriction causing slow draw and potential plunger stress. A 1 ml intramuscular draw with a standard 23–25 gauge needle is more practical. At 76.5 mg/ml, a 1 ml injection delivers exactly 76.5 mg of Trenbolone Hexahydrobenzylcarbonate — a useful calculation point for structuring weekly androgen load. (2) angle_used

Manufacturer

Kim Pharma's approach to product authentication for its Parabolan 76.5mg/ml line centres on a dual-layer verification architecture that operates at both the physical vial and the digital record level. Each vial leaving the filling line receives a tamper-evident holographic seal whose optical properties cannot be reproduced by standard printing or copying methods, paired with a unique alphanumeric authentication code printed beneath the hologram layer. That code is registered against Kim Pharma's batch database at the point of production — not retrospectively — so a legitimate vial's code returns a confirmed match, lot number, and associated analytical data when queried through the brand's verification channel. Counterfeiting detection is therefore built into the product rather than dependent on post-market surveillance alone. For athletes sourcing Parabolan 76.5mg/ml across multiple vials within a cycle, the serialised code structure also allows cross-referencing of individual vials to confirm they originate from the same production batch, providing assurance that concentration consistency between vials reflects a single verified HPLC result rather than independent untested units.

Product details

BrandKim Pharma
Active ingredienttrenbolone hexahydrobenzylcarbonate
Also known asParabolan, Tren Hex, Trenbolone Hexa, Kim Pharma Parabolan
Strength76.5 mg
FormVial
Pack size1 piece
Item numberINJ-THEX-KIM-76.5-014

Reviews

No reviews yet. Be the first to review this product.

Write a review

Your rating *

Your review will be checked before publication.

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Parabolan 100mg/ml 10x1ml Ampoules by Balkan PharmaceuticalsEstablished Brand

Parabolan 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

€58.00
Parabol-100 100mg/ml 10x1ml Ampoules by BM PharmaceuticalsLong-Acting Formula

Parabol-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

€64.00
Parabolan 100 100mg/ml 10ml Vial by Dragon-PharmaHigh Concentration

Parabolan 100 100mg/ml 10ml Vial by Dragon-Pharma

€68.00
Hexos 75mg/ml 10ml Vial by Driada MedicalBrand Quality

Hexos 75mg/ml 10ml Vial by Driada Medical

€70.00

Stack it with

Pairs well with these products.

Quant-Equipoise 300mg/ml 10ml Vial by Beligas PharmaceuticalsHigh Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

€47.00
Bolden-250 250mg/ml 10x1ml Ampoules by BM PharmaceuticalsLong-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

€48.00
EquiTrex 350mg/ml 10ml Vial by Concentrex LabsBrand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

€52.00
EQ 300 300mg/ml 10ml Vial by Dragon-PharmaPro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

€44.00